Agena Bioscience e HeartGenetics estabelecem parceria comercial

HeartGenetics and Agena Bioscience announced today a co-promotion agreement leveraging Agena ’s MassARRAY® DX clinical diagnostics technology with HeartGenetics’ CE-IVD marked products for cardiovascular testing.
The MassARRAY System provides a streamlined and cost-effective workflow for labs enabling parallel analysis of mutations (SNPs, InDels, rearrangements and copy number variants). Tens to hundreds of medically-actionable or known predictive genetic variants can be screened across 100s of patient samples in a single day. The flexibility and scalability of the platform permit mid- to large-scale sample throughput which provides the means for highly efficient lab production.

As a leader in genetic tests and computational tools designed to support clinical diagnosis and the prevention of cardiovascular disease, HeartGenetics will provide HEARTDECODE ® software and assays designed for use with the MassARRAY System. HEARTDECODE® software provides highly accurate and reproducible analysis with the integration of both genetic and pharmacogenetics data and medical guidelines.

“Computational biology companies with clinical expertise are cr ucial for realizing the full potential of personalized medicine. We are proud that HeartGenetics, one of the key entrepreneurs in digital health care, has chosen to partner with Agena,”

said David Coorey, Vice President and General Manager, EMEA at Agena Bioscience.

HeartGenetics, a spin-off from Tecnico Lisboa, has developed new certified CE-IVD medical devices, which include genetic tests and AI software tools for data interpretation, to assess the individual risk for conditions such as Hereditary Thrombophilia (TRB), Arterial Hypertension (AHTN), Hypertrophic Cardiomyopathy (HCM), and Familial Hypercholesterolemia (FH). Additionally, the clinically relevant genetics tests of Warfarin, Clopidogrel and Simvastatin pharmacogenetics are included.

Ana Teresa Freitas, Chief Executive Officer of HeartGenetics, commented

“We are excited to have the opportunity to partner with Agena Bioscience, whose MassARRAY technology provides an ideal platform for robust, cost-effective clinical diagnostics. Together we will be able to promote cardiovascular health to many patients with accurate, actionable and affordable testing.”

links relacionados:

Prémio Idea Puzzle 2012
Nonius celebra acordo de princípio com o grupo Impresa
Biosurfit recebe a Marcação CE para teste da diabetes
A HeartGenetics foi seleccionada para a World Health Summit
Beta Capital desinveste na Nonius: uma história de sucesso
Magnomics vence maior concurso mundial de Saúde Animal
Nonius é líder na gestão de Internet para Hotéis na América Latina
Biosurfit em grande destaque no mercado Benelux
Nonius compra a TendiQ e incorpora Nonius Europe

ver noticias em arquivo
ver noticias por participada
Biocant Ventures, Lda.
Biosurfit, S.A.

Quem somos

Politica de investimento
O seu projecto